RM-TRS / Tissue, repair and matrix signalling
Larazotide acetate
Also known as: AT-1001 · INN-202
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Larazotide acetate is a defined synthetic peptide developed for local oral activity at intestinal tight-junction signaling. AT-1001 and INN-202 are development names found in the literature.
Evidence position
Several controlled human studies support Grade B. Results vary by dose and endpoint, so the page keeps positive, null and exploratory findings in the same record.
What the record does not establish
Clinical-trial material does not authenticate a supplier lot, a capsule sold under a similar name, or any route and formulation outside the studied protocol.
Sources
- 01Larazotide acetate for persistent celiac-disease symptoms: randomized controlled trialPubMed
- Shows
- A 342-adult randomized trial in which the lowest studied dose met the primary symptom endpoint
- Does not show
- Higher doses did not meet the endpoint; one condition, oral formulation and controlled protocol
- 02Larazotide acetate during gluten challenge: randomized placebo-controlled studyPubMed
- Shows
- Human exploratory trial with mixed permeability, symptom and immune-reactivity findings
- Does not show
- Does not establish approval or equivalence of a separately sourced material
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Larazotide Acetate
- CID
- 44146842
- Formula
- C34H59N9O12
- Mass
- 785.9
PUBMED / FOUND RECORDS
- Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection.European heart journal / 2023 Apr 7PMID 36638776 / DOI 10.1093/eurheartj/ehac823
- Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.Nature communications / 2020 Apr 24PMID 32332732 / DOI 10.1038/s41467-020-15831-7
- Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.Gut / 2026 Mar 6PMID 40579122 / DOI 10.1136/gutjnl-2025-335373
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation.American journal of physiology. Gastrointestinal and liver physiology / 2021 Jun 1PMID 33881350 / DOI 10.1152/ajpgi.00386.2020
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.Alimentary pharmacology & therapeutics / 2013 JanPMID 23163616 / DOI 10.1111/apt.12147
CLINICALTRIALS.GOV / FOUND RECORDS
- A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac DiseaseCOMPLETED / PHASE2 / 9 Meters Biopharma, Inc.NCT01396213 / DIRECT intervention MATCH: Larazotide acetate
- AT1001 for the Treatment of Long COVIDACTIVE_NOT_RECRUITING / PHASE2 / Massachusetts General HospitalNCT05747534 / DIRECT intervention MATCH: Larazotide acetate
- Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac DiseaseCOMPLETED / PHASE2 / 9 Meters Biopharma, Inc.NCT00492960 / DIRECT intervention MATCH: Larazotide acetate
- Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac DiseaseCOMPLETED / PHASE2 / 9 Meters Biopharma, Inc.NCT00620451 / DIRECT intervention MATCH: Larazotide acetate
- Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD SymptomsTERMINATED / PHASE3 / 9 Meters Biopharma, Inc.NCT03569007 / DIRECT title MATCH: Larazotide acetate